Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, is advancing its oncology research with strategic support from a Department of Defense grant. The company is currently developing two promising clinical trials for its lead candidate ENV105, targeting prostate and EGFR-dependent non-small cell lung cancers, with safety and interim efficacy results anticipated in the second quarter of 2025.
The company's research focuses on a novel approach to addressing cancer treatment challenges. ENV105, an antibody targeting CD105, aims to overcome drug resistance mechanisms that frequently lead to treatment failure. By targeting CD105, a protein identified as a key driver of treatment resistance, the therapy seeks to restore the effectiveness of standard cancer treatments across multiple cancer types.
In addition to ENV105, Kairos is developing KROS101, an immune response modulator, and has recently presented data at key oncology conferences. The company's strong financial position is supported by non-dilutive government grants and growing analyst coverage from firms such as EF Hutton and HC Wainwright.
The current clinical trials represent significant potential in addressing unmet medical needs in cancer treatment. ENV105's Phase 2 trial for castrate-resistant prostate cancer and Phase 1 trial for lung cancer demonstrate the company's commitment to developing innovative therapeutic strategies that could potentially improve patient outcomes and overcome current treatment limitations.
